Fighting Fire with Fire: Mobileum and Apate Shut Down Scam Operations From the Inside Out
9.9.2026 09:00:00 CEST | Business Wire | Press Release
Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, and Apate.ai (“Apate”) have announced a partnership that equips communications service providers (CSPs) with advanced AI-powered fraud prevention capabilities designed to detect, disrupt, and investigate scam call operations.
According to the Global Anti-Scam Alliance, scammers stole an estimated $442 billion in 2025, with phone calls, text messages and emails being the top three communication channels used by scammers. Through the integration of Mobileum’s Active Intelligence Platform with Apate's conversational AI agents, CSPs can now move beyond traditional call blocking and take a more proactive role in disrupting scam activity.
Rather than simply preventing suspicious calls, messages and other communications from reaching customers, the solution engages fraudsters directly, collecting valuable intelligence that helps identify tactics, uncover networks, expose the artifacts they use (bank accounts, payment instruments, malicious URLs) and prevent future attacks on subscribers. For example, when a suspicious call is detected, it is diverted to a network of lifelike conversational AI agents that simulate real conversations with the scammer. Over tens of thousands of interactions per day, this continuously builds a unique dataset of real-time scam intelligence, which is fed straight into Mobileum’s security and fraud prevention solutions to eliminate criminal operations on a faster and larger scale than human effort alone could achieve.
"With AI, fraudsters are moving faster and are constantly changing the playing field. Traditionally, CSPs could only react to threats and had little insight into who was behind them. By combining Mobileum’s security and fraud prevention solutions with Apate's conversational AI, we're empowering CSPs to detect emerging threats faster, strengthen their network defenses, and stay ahead of increasingly sophisticated fraud operations,” commented Bernardo Lucas, Risk Management Business Unit Leader.
“Apate was built to dismantle scam operations, which are becoming increasingly industrialized and AI-driven. Because of this, we are seeing a global, coordinated effort from CSPs, banks, regulators and governments to tackle scams in a more proactive way. We fight back by using our advanced AI to engage scammers, gather real-time intelligence, and expose criminal tactics from within. Together with Mobileum, we're enabling CSPs to stop fraudsters before any real customers are put at risk,” commented Brad Joffe, Co-founder and Chief Commercial Officer at Apate.ai.
Together, Mobileum and Apate are redefining fraud and scam prevention for the AI era, turning it from a defensive, reactive function into an intelligence-driven operation. As scam tactics grow more sophisticated and harder to detect, this partnership gives CSPs a critical edge: the ability to see threats coming, act on real intelligence, and cut off criminal activities before they scale. The result is fewer fraud losses, stronger customer trust, and a communications ecosystem that's better equipped to stay ahead of tomorrow's threats.
For more information, visit www.apate.ai
About Mobileum Inc.
Mobileum is a leading provider of Telecom analytics solutions for roaming, core network, security, risk management, domestic and international connectivity testing, and customer intelligence. More than 1,000 customers rely on its Active Intelligence platform, which provides advanced analytics solutions, allowing customers to connect deep network and operational intelligence with real-time actions that increase revenue, improve customer experience, and reduce costs. Headquartered in Silicon Valley, Mobileum has global offices in Australia, Germany, Greece, India, Japan, Portugal, Singapore, UK, and United Arab Emirates. Learn more at www.mobileum.com
About Apate.ai
Apate.ai is an autonomous intelligence and disruption platform built to fight fraud at scale. Its lifelike AI agents engage scammers across voice, SMS, chat and email, waste their resources, and turn every scam attempt into real-time intelligence its clients can act on. A spin-out of Macquarie University's Cyber Security Hub and headquartered in Sydney, Apate works with tier-1 telcos, banks and government agencies across APAC, Europe, Africa the Middle East and North America. Apate.ai a member of the Global Anti-Scam Alliance and GSMA. Learn more at www.apate.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20260909237431/en/
Contacts
Media Contacts:
QUEXOR GROUP INC.
Cheryl Fritz | cfritz@quexor.com | Mob.: +1 (703) 856-5932
Media and Corporate Communications – Mobileum
Sandra Almeida | sandra.almeida@mobileum.com | Mob. +351 939650229
Media and Corporate Communications – Apate.ai
Brad Joffe | brad@apate.ai | Mob. +61 416 109 769
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom